Recent scientific inquiry delves into the complex relationship between dietary choices and blood sugar management, with a particular focus on dairy products. Researchers have investigated whether specific components like whey protein, consumed strategically before meals, can mitigate undesirable post-meal blood sugar surges. This comprehensive review examines various dairy types—from whole milk to probiotic yogurts—and their potential influence on glucose regulation.
Published in the journal Nutrients, a recent narrative review meticulously analyzed data from 57 randomized controlled trials. These trials aimed to ascertain the effects of milk and diverse dairy products on glycemic control among adults diagnosed with type 2 diabetes mellitus (T2DM) and prediabetes. The investigation spanned both immediate and sustained dietary interventions, scrutinizing how variations in dairy composition, fat content, and protein types might modulate human glucose metabolism.
The researchers observed that a broad increase in dairy consumption generally yielded mixed and often negligible long-term impacts on glycated hemoglobin (HbA1c) levels. However, more focused dietary approaches, such as consuming structured whey protein preloads before meals, consistently demonstrated a reduction in acute post-meal glycemic excursions. This beneficial effect is posited to stem from influences on incretin hormones, the body's insulin production, and the rate at which the stomach empties its contents.
Type 2 diabetes and prediabetes represent significant global health challenges, characterized by dysregulated glucose metabolism and an elevated susceptibility to cardiovascular complications. Decades of research have attributed these conditions to insulin resistance—a diminished cellular responsiveness to insulin—and a progressive decline in pancreatic beta-cell function. This understanding has historically shaped dietary recommendations, often advocating for a reduction in saturated fat intake due to its association with increased cardiovascular risks.
Despite these established guidelines, the scientific community holds diverging views on the metabolic implications of dairy products. The 2025–2030 Dietary Guidelines for Americans, for instance, endorse the daily consumption of full-fat dairy devoid of added sugars. Yet, clinical studies present conflicting evidence regarding whether dairy fats and proteins protect against or exacerbate metabolic deterioration. The necessity for thorough reviews of past trials arises from the variability in research designs, including the types of dairy products studied, their formulations, and the measured outcomes. This heterogeneity makes direct comparisons difficult and leaves lingering questions about the specific roles of fermentation, fortification, and isolated dairy proteins.
The review's methodology involved a narrative synthesis of randomized controlled trials identified through PubMed up to April 7, 2026. While not strictly adhering to PRISMA guidelines, the authors employed a PRISMA-style flow diagram to detail their selection process. Out of 246 initial records, 176 were screened after duplicate removal, ultimately leading to the inclusion of 57 studies—46 focusing on T2DM and 11 on prediabetes. Interventions were categorized by dairy type, encompassing fluid milk with varying fat percentages, fermented products such as yogurt and kefir, fortified dairy items enriched with specific nutrients or prebiotics, and isolated dairy proteins, predominantly whey and casein. Key physiological markers assessed included fasting plasma glucose (FPG), HbA1c, fructosamine, insulin resistance measures like HOMA-IR, and postprandial incretin concentrations, such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP).
Across the trials, sustained dairy consumption did not consistently provide uniform glycemic benefits, with specific product formulations largely dictating the outcomes. Numerous randomized controlled trials indicated that increasing the intake of low-fat or high-fat dairy to three or more servings daily did not significantly alter participants’ HbA1c, fasting glucose, or HOMA-IR levels when compared to their usual diets. Intriguingly, one study involving overweight adults, including some with prediabetes, revealed that a diet rich in low-fat dairy led to greater insulin resistance than a red-meat-based diet, particularly observed in women. Conversely, a 12-week trial involving 48 adults with T2DM showed that a high-energy breakfast supplemented with whey protein reduced HbA1c by 0.89 percentage points, outperforming breakfasts rich in other proteins or carbohydrates. Nevertheless, other studies found no additional HbA1c benefits when whey was combined with exercise regimens. Certain fortified and fermented dairy products, like vitamin D- and calcium-enriched yogurt drinks, demonstrated improvements in some glycemic and insulin sensitivity indicators, although these effects varied and might be attributable more to the added nutrients than to the dairy itself.
In trials focused on prediabetes, yogurt containing heat-treated Lactiplantibacillus plantarum (OLL2712) led to a modest reduction in participants’ HbA1c over 12 weeks compared to conventional yogurt, though this difference was not sustained eight weeks post-treatment. Another smaller study indicated that a milk protein hydrolysate preload helped over half of 21 participants return their HbA1c below the prediabetes threshold after six weeks, though sustained remission was not established. Preload studies generally indicated that consuming 15 to 50 grams of whey protein prior to meals could enhance short-term postprandial glucose regulation, although the optimal dosage and timing are yet to be precisely determined. For instance, in one trial with 15 adults with T2DM, a 50-gram whey preload taken 30 minutes before breakfast reduced overall post-meal glucose exposure by 28% and boosted insulin and intact GLP-1 responses compared to consuming water. However, higher insulin or incretin concentrations did not always correlate with improved glucose control. Notably, an acute trial involving 22 men with T2DM found that combining a whey preload with the dipeptidyl peptidase-4 (DPP-4) inhibitor vildagliptin improved post-meal glucose regulation more effectively than either intervention alone, suggesting a promising area for future research.
The collective evidence underscores that dairy products are not uniform in their metabolic impact; rather, their effects are significantly influenced by their matrix structure, processing methods, dosage, fortification, and timing of consumption. While a general increase in dairy intake may not consistently lead to glycemic improvements, targeted strategies such as structured whey protein preloads and specific fermented yogurt formulations show promise. These interventions could serve as affordable and accessible adjuncts to existing diabetes care, complementing established dietary and medical treatments. However, their long-term efficacy and impact on beta-cell function require further investigation.
The authors acknowledge limitations in most current chronic intervention trials, primarily their short durations—typically between 4 and 24 weeks—and small sample sizes. They advocate for future research to involve larger, longer, and more demographically balanced trials, including real-world assessments, to confirm sustained benefits and adherence. Additionally, further studies are needed to explore potential interactions between whey preloads and modern glucagon-like peptide-1 receptor agonists (GLP-1 RAs), as such combinations might enhance glucose regulation but could also exacerbate gastrointestinal side effects. These insights are crucial for refining medical nutrition therapy and improving outcomes for individuals managing T2DM and prediabetes.
